A carregar...
Publicação
Desenvolvimento de um painel de imunofenotipagem para lesões proliferativas do fígado em cães
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.82 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
O diagnóstico definitivo das lesões hepáticas proliferativas depende da avaliação histopatológica dos tecidos. No entanto, esta pode, por vezes, ser difícil, devido às semelhanças entre as características histológicas que as várias neoplasias hepáticas podem apresentar. Assim, é necessário recorrer a técnicas auxiliares de diagnóstico, nomeadamente a imunohistoquímica. Atualmente, esta técnica já é utilizada por rotina em muitos Laboratórios de Medicina Humana, sendo a sua utilização menos comum em Medicina Veterinária. Assim, com o intuito de expandir o uso de marcadores imunohistoquímicos no diagnóstico de doenças proliferativas do fígado canino, foi estudada a marcação de um painel de anticorpos, nomeadamente, CA19-9, CA-125, CD71, CEA, CK7, CK19, Ep-CAM, Hep-Par 1, TTF-1 e p63, em várias lesões proliferativas hepáticas. Destes anticorpos apenas quatro, Hep-Par 1, p63, TTF-1 e CD71, apresentaram marcação específica nos tecidos selecionados, e prosseguiram no estudo. Foram utilizadas amostras de fígado normal e de lesões proliferativas (hepáticas e não hepáticas) caninas de 33 casos do arquivo do Laboratório de Anatomia Patológica da Faculdade de Medicina Veterinária da Universidade de Lisboa. Todos os casos foram submetidos a imunohistoquímica com o painel de 4 anticorpos selecionado. A intensidade de marcação e proporção de células marcadas foi avaliada, obtendo-se uma pontuação final para a marcação de cada anticorpo em cada caso. Os resultados foram avaliados com métodos de estatística descritiva. O Hep-Par 1 foi um marcador altamente sensível e específico para a distinção entre lesões proliferativas hepatocelulares e não-hepatocelulares, não permitindo distinguir entre lesões hepatocelulares benignas e malignas; o p63 e o CD71 não foram expressos em lesões hepatocelulares, tendo sido expressos em colangiocarcinomas e algumas neoplasias hepáticas metastáticas; o TTF 1, clone SP141, não demonstrou utilidade no diagnóstico de neoplasias hepáticas. Os resultados deste estudo representam um ponto de partida para estudos futuros, que permitam elaborar um painel completo para diagnóstico de lesões proliferativas no fígado canino
The definitive diagnosis of proliferative hepatic lesions depends on the histopathological evaluation of tissue samples. However, this can sometimes be challenging due to similarities between the histological features exhibited by various hepatic neoplasms. Therefore, it is necessary to rely on auxiliary diagnostic techniques, particularly immunohistochemistry. Currently, this technique is routinely used in many human medical laboratories but its application is less common in Veterinary Medicine. With the aim of expanding the use of immunohistochemical markers in the diagnosis of canine proliferative liver diseases, the expression of a panel of antibodies, namely CA19-9, CA-125, CD71, CEA, CK7, CK19, Ep-CAM, Hep-Par 1, TTF-1, and p63, was studied in various proliferative hepatic lesions. Of these antibodies, only four (Hep-Par 1, p63, TTF-1, and CD71) showed specific staining in the selected tissues and were therefore included in the subsequent study. Samples of normal liver and proliferative (hepatic and non-hepatic) lesions from 33 canine cases archived at the Laboratory of Pathological Anatomy of the Faculty of Veterinary Medicine of the University of Lisbon were used. All cases were subjected to immunohistochemistry with the selected panel of four antibodies. The staining intensity and proportion of labeled cells were assessed, yielding a final score for each antibody in each case. The results were evaluated using descriptive statistical methods. Hep-Par 1 proved to be a highly sensitive and specific marker for distinguishing between hepatocellular and non hepatocellular proliferative lesions, though it did not differentiate between benign and malignant hepatocellular lesions. p63 and CD71 were not expressed in hepatocellular lesions but were expressed in cholangiocarcinomas and some metastatic hepatic neoplasms. TTF-1 (clone SP141) showed no diagnostic utility for hepatic neoplasms. The findings in this study represent a starting point for future research aimed at developing a comprehensive panel for the diagnosis of proliferative lesions in the canine liver
The definitive diagnosis of proliferative hepatic lesions depends on the histopathological evaluation of tissue samples. However, this can sometimes be challenging due to similarities between the histological features exhibited by various hepatic neoplasms. Therefore, it is necessary to rely on auxiliary diagnostic techniques, particularly immunohistochemistry. Currently, this technique is routinely used in many human medical laboratories but its application is less common in Veterinary Medicine. With the aim of expanding the use of immunohistochemical markers in the diagnosis of canine proliferative liver diseases, the expression of a panel of antibodies, namely CA19-9, CA-125, CD71, CEA, CK7, CK19, Ep-CAM, Hep-Par 1, TTF-1, and p63, was studied in various proliferative hepatic lesions. Of these antibodies, only four (Hep-Par 1, p63, TTF-1, and CD71) showed specific staining in the selected tissues and were therefore included in the subsequent study. Samples of normal liver and proliferative (hepatic and non-hepatic) lesions from 33 canine cases archived at the Laboratory of Pathological Anatomy of the Faculty of Veterinary Medicine of the University of Lisbon were used. All cases were subjected to immunohistochemistry with the selected panel of four antibodies. The staining intensity and proportion of labeled cells were assessed, yielding a final score for each antibody in each case. The results were evaluated using descriptive statistical methods. Hep-Par 1 proved to be a highly sensitive and specific marker for distinguishing between hepatocellular and non hepatocellular proliferative lesions, though it did not differentiate between benign and malignant hepatocellular lesions. p63 and CD71 were not expressed in hepatocellular lesions but were expressed in cholangiocarcinomas and some metastatic hepatic neoplasms. TTF-1 (clone SP141) showed no diagnostic utility for hepatic neoplasms. The findings in this study represent a starting point for future research aimed at developing a comprehensive panel for the diagnosis of proliferative lesions in the canine liver
Descrição
Dissertação de Mestrado Integrado em Medicina Veterinária, área científica de Sanidade Animal
Palavras-chave
Imunohistoquímica Fígado Cão Neoplasias hepáticas Immunohistochemistry Liver Dog Hepatic neoplasms